Tumor growth, progression, and response to the hypoxic tumor microenvironment involve the action of hypoxia-inducible transcription factors, HIF1 and HIF2. HIF is a heterodimeric transcription factor containing an inducible HIFa subunit and a constitutively expressed HIFb subunit. The signaling pathways operational in macrophages regulating hypoxia-induced HIFa stabilization remain the subject of intense investigation. Here, it was discovered that the PTEN/PI3K/AKT signaling axis controls hypoxia-induced HIF1a (HIF1A) and HIF2a (EPAS1) stability in macrophages. Using genetic mouse models and pan-PI3K as well as isoform-specific inhibitors, inhibition of the PI3K/AKT pathway blocked the accumulation of HIFa protein and its primary transcriptional target VEGF in response to hypoxia. Moreover, blocking the PI3K/AKT signaling axis promoted the hypoxic degradation of HIFa via the 26S proteasome. Mechanistically, a macrophage-dominant PI3K isoform (p110g) directed tumor growth, angiogenesis, metastasis, and the HIFa/VEGF axis. Moreover, a pan-PI3K inhibitor (SF1126) blocked tumor-induced angiogenesis and inhibited VEGF and other proangiogenic factors secreted by macrophages. These data define a novel molecular mechanism by which PTEN/PI3K/AKT regulates the proteasome-dependent stability of HIFa under hypoxic conditions, a signaling pathway in macrophages that controls tumor-induced angiogenesis and metastasis.
Introduction
Hypoxia is considered a hallmark of tumor progression in that it induces neoangiogenesis, the recruitment of bone marrow-derived cells, and degradation of extracellular matrix (ECM) resulting in activation of proliferation, invasion, and metastasis of cancer cells (1) . Hypoxic regions of tumors are characterized by an increased accumulation of macrophages which contributes to tumor angiogenesis and tumor progression (2) . Hypoxic macrophages are known to respond to hypoxia by upregulating hypoxia-inducible transcription factors (HIF) consisting of distinct, hypoxiaresponsive (HIF1a and HIF2a) subunits and identical, constitutively expressed (HIF1b and HIF2b) subunits (3, 4) . In the presence of oxygen, the a subunits are hydroxylated by oxygen-sensitive enzymes, prolyl hydroxylases, which targets them for degradation by the von Hippel-Lindau (VHL)-dependent ubiquitin-proteasomal pathway (5, 6) . Under hypoxic conditions, HIFa subunits are stabilized, translocate to the nucleus, and, together with their partner factor, basic-helix-loop-helix/PAS protein Arnt, bind to the promoters of genes that mediate glycolysis and neovascularization/angiogenesis (7, 8) .
There are conflicting views of the relative contribution of each HIF to the regulation of hypoxic gene expression in macrophages. Some studies suggest that the main form of HIF upregulated by tumor-associated macrophages (TAM) is HIF2 (9, 10) , and overexpression of HIF2a in normoxic human macrophages upregulates various proangiogenic genes (11) . However, human macrophages also markedly upregulate HIF1a when exposed to hypoxia in vitro and in tumors (12) , and HIF1a-deficient murine macrophages express lower levels of such HIF-regulated genes such as VEGF and the glucose receptor GLUT1 in hypoxia than their wild-type (WT) counterparts. Interestingly, the exact contribution of HIF1a and HIF2a to the regulation of hypoxic gene expression appears to vary between different cell types (7) .
The molecular mechanisms controlling HIFa accumulation in macrophages are not completely elucidated. In the tumor cells, a large number of signaling pathways, including Rac-GTP, Src, Fak, PI3K, etc., have been linked to the control of HIF1a and VEGF (13, 14) . Several groups have implicated the role of PTEN/PI3K signaling in the regulation of HIF1a (15) (16) (17) in tumor cells. However, the exact contribution of the PI3K pathway to HIFa regulation remains a subject of considerable interest and controversy in both the tumor and stromal compartments (18, 19) .
PI3K are a family of enzymes that phosphorylate phosphatidylinositol (PI) lipids at the 3 0 position (20) . The PTEN deleted on chromosome 10 (PTEN) is a dual specificity phosphatase that antagonizes the enzymatic activity of PI3K by dephosphorylating phosphatidylinositol (3, 4, 5 )trisphosphate to generate phosphatidylinositol (4,5)-biphosphate. PI3K/PTEN has been shown to play a prominent role in regulating a number of cellular responses, including growth, survival, and migration (21, 22) . PI3K is known to be associated with different phases of macrophage function (23) . The PI3K/Akt signaling axis is crucial for migration and diapedesis of immune effector cells, such as neutrophils and monocytes, to the site of inflammation and infection (24) (25) (26) . The role of myeloid-specific PTEN in controlling lung infection and inflammation during murine pneumococcal pneumonia and neutropenia-associated pneumonia is also well-studied (27, 28) .
However, the contribution of PTEN/PI3K/AKT pathway in enhancing HIFa-mediated gene expression in macrophages has not been previously reported. In the present study, using myeloid-specific deletion of PTEN and various pan and isoform-specific PI3K inhibitors, we show that PTEN/PI3K signaling controls hypoxia-induced HIF1a and HIF2a stabilization in macrophages. Moreover, using p110g À/À mice and pan-PI3K inhibitor SF1126, we demonstrate that PI3K signaling promotes tumor growth and metastasis in tumor models by increasing the expression and potential secretion of proangiogenic factors by TAMs.
Materials and Methods

Animal studies
All procedures involving animals were approved by the University of California San Diego Animal Care Committee, which serves to ensure that all federal guidelines concerning animal experimentation are met. PI3K g (p110g À/À ) mice were obtained from Dr. Joseph Penninger, Institute of Molecular Biotechnology (Vienna, Austria). Floxed PTEN mice and lysozyme M (LysM) Cre recombinase transgenic mice were purchased from Jackson laboratories. LysM Cre mice were mated with PTEN fl / fl mice to delete PTEN from myeloid cell compartment. Depending on the presence of LysM Cre recombinase, double-floxed PTEN fl / fl mice are referred to as PTEN MC-KO or PTEN MC-Wt mice, respectively. Macrophages from PTEN fl / fl mice were used as WT controls.
Antibodies and reagents
Macrophage colony-stimulating factor (MCSF) was from Gibco Life technologies. PI-103, BKM120, and PF4691502 were purchased from Selleck chemicals. SF2523 and SF1126 were obtained from SignalRx Pharmaceuticals (29, 30) . Primary or fluorescent antibodies against CD31 (clone MEC13.3) and CD11b (clone M1/70) were from BD Biosciences; F4/80 (clone BM8) was from eBiosciences. Alexa Flour 488 was from Invitrogen life Technologies. Bouin's solution, 4,6 0 -diamidino-2-phenylindole (DAPI), hyaluronidase type V, and DNase I were from Sigma.
Isolation of bone marrow-derived macrophages, hypoxia and in vitro inhibitor experiments
Bone marrow-derived macrophages (BMDM) were isolated as described previously and cultured under MCSF (75 ng/mL) þ 20% FBS conditions (31) . On day 7, most of the adherent cells were macrophages as confirmed by FACS analysis (>90% Mac1-and F4/80-positive cells). To study the effect of different inhibitors in vitro, macrophages (7 days in culture) were treated with or without pan or isoformspecific PI3K inhibitors followed by hypoxia (1% O 2 ) for 4 hours. For hypoxia experiments, macrophages were placed in a modulator incubator chamber (Billups-Rothenberg, Inc.) that was flushed with a gas mixture consisting of 1% O 2 , 5% CO 2 , with balance N 2 , sealed, and incubated at 37 C. Whole-cell lysates were prepared in RIPA buffer (Cell Signaling Technologies) containing complete protease inhibitor cocktail. For HIFa immunoblots, nuclear extracts were prepared using Dignam protocol (32) .
Plasmid and siRNA transfections
BMDMs were transfected using an AMAXA Mouse Macrophage Nucleofection Kit (Lonza) with 5 mg of HA-PTEN or myrAKT plasmid or 100 nmol/L of siRNA for PI3Ka (Mm_pik3ca_1), PI3Kb (Mm_pik3cb_2), PI3Kg (Mm_pik3cg_1), PI3Kd (Mm_pik3cd_1), Akt1/2 siRNA or nonsilencing siRNA (Ctrl_AllStars-1) purchased from Qiagen or Akt1/2 siRNA and control siRNA purchased from Santa Cruz Biotechnology. After transfection, cells were cultured for 36 hours. Each siRNA was tested individually for efficient knockdown of protein expression.
Quantification of gene expression
Total RNA was isolated from BMDMs using RNAeasy kit (Qiagen). cDNA was prepared from 1 mg RNA sample using iScript cDNA synthesis kit (Bio-Rad). cDNA (2 mL) was amplified by RT-PCR reactions with 1Â SYBR green supermix (Bio-) in 96-well plates on an CFX96 Real time system (Bio-Rad), using different primers for mouse gene. Sequence of primers used were reported before (31) . Relative expression levels were normalized to GAPDH expression according to the formula: 2 Ct_gene of interest À Ct_GAPDH . Values are multiplied by 100 for presentation purposes.
Immunoblotting
Whole-cell extract (WCE) or nuclear extracts of BMDMs were prepared and protein was quantitated with Bio-Rad protein assay kit (Bio-Rad Laboratories) using BSA as a standard. Equal protein from protein lysates were resolved by SDS-PAGE, followed by immunoblotting and probing with primary antibodies against p110a (Cell Signaling Technologies), p110b (Santa Cruz), p110g (Cell Signaling Technologies) and p110d (Santa Cruz), pAKT (Cell Signaling), AKT (Cell Signaling), HIF1a and HIF2a (Novus Biological), and b-actin (Santa Cruz).
In vivo tumor experiments
Lewis lung carcinoma (LLC) and B16 F10 melanoma obtained from the ATCC were cultured as described previously (31) . LLC cells (1 Â 10 5 ) were injected subcutaneously into syngeneic 4-to 6-week-old mice. Tumor dimensions were recorded regularly, and tumors were harvested 25 days postinjection. Tumor volume was measured using the following formula: Volume ¼ 0.5 Â length Â (width) 2 . For experimental metastasis, B16 F10 melanoma cells (5 Â 10 5 ) were injected intravenously, and lungs were harvested after 15 days as described before (31) . For drug treatment studies, WT mice implanted subcutaneously with 1 Â 10 5 LLC cells were treated with vehicle or 50 mg/kg SF1126 subcutaneously 3 times a week for 28 days, until tumors were harvested. For B16 F10 melanoma, 2 doses of 50 mg/kg of SF1126 were given before injecting 5 Â 10 5 B16F10 melanoma cells, followed by daily treatment with the drug until lungs were harvested on day 15. For survival studies, 3 doses of 50 mg/kg of SF1126 were given before injecting 3 Â 10 5 B16F10 melanoma cells, followed by daily treatment until mice died. Tumor volumes and weights were measured and the tumors were used for immunofluorescence, IHC, and sorting of macrophages using FACS. For FACS analysis, LLC tumors were excised, minced, and digested to single-cell population as described (31) . CD11band F4/80-positive cells sorted by FACS were used for RNA isolation and real-time PCR studies.
Results
PTEN regulates expression of HIFa protein and HIFa mRNA targets in macrophages
The tumor suppressor PTEN is an antagonist of PI3K signaling and functions by removing the phosphate at the D3 position of phosphatidylinositol trisphosphate and phosphatidylinositol bisphosphate. To validate the role of PTEN in hypoxia-induced HIFa stabilization, we generated conditional PTEN knockout mice in which PTEN expression was controlled by LysM, a myeloid cell-specific promoter (20) . Depending on the presence of LysM Cre recombinase, double-floxed PTEN fl / fl mice are referred to as PTEN MC-KO or PTEN MC-Wt mice, respectively. Deletion of PTEN was confirmed in primary macrophages (Fig. 1A) , and resulting downstream effects of constitutively active PI3K were reflected by greatly elevated baseline levels of phospho-Akt in PTEN MC-KO macrophages (Fig. 1A) . Myeloid-specific deletion of PTEN induced high levels of HIF1a and HIF2a stabilization in PTEN MC-KO mice as compared with PTEN MC-Wt (Fig. 1B) . These results were also supported by a greater degree of HIFa stabilization in BMDMs isolated from PTEN þ/À mice (Fig. 1C ). Our next point of focus was to investigate the role of PTEN in the transcriptional activation of the HIFa target gene VEGF. Loss of PTEN in myeloid cell compartment increased VEGF mRNA levels in PTEN MC-KO mice (Fig. 1D ). To further validate the role of PTEN in stabilization of HIFa, PTEN was exogenously expressed in PTEN MC-ko mice. Results in Fig. 1E showed that expression of PTEN blocked the accumulation of HIFa in PTEN MC-ko mice. Taken together, these results suggest a role for PTEN in the regulation of the HIFa/VEGF axis under hypoxia in macrophages ( Fig. 1 ).
Inhibition of PI3K/AKT pathway blocks the hypoxic induction of HIF1a and HIF2a and its transcriptional target VEGF in macrophages
The observation that PTEN exerts control over HIF1a and HIF2a protein expression and transcriptional activity ( Fig. 1 ) led us to investigate the effects of different clinically relevant PI3K inhibitors (SF1126, PF4691502, PI-103, and BKM120) on the hypoxic induction of HIFa in macrophages. SF1126, a pan-PI3K inhibitor, is a vascular RGDS/ integrin targeted prodrug derivative of LY294002 and is entering phase II clinical trials (29) . The other inhibitors used in early-phase clinical trials include: PI-103, a dual PI3K/mTOR inhibitor; PF4691502, a pan-PI3K inhibitor; and BKM120, a pan-PI3K inhibitor (33) (34) (35) . The results shown in Fig. 2A clearly demonstrate that SF1126, PI-103, PF4691502, and BKM120 potently inhibit the hypoxic induction of HIF1a and HIF2a in BMDMs. Furthermore, these pan-PI3K inhibitors also blocked the transcriptional activation of HIFa target gene, VEGF (Fig. 2B ). In addition to pan-PI3K inhibitors in clinical trial, we used SF2523, a novel pan-PI3K inhibitor developed in collaboration with SignalRx Pharmaceuticals (30) , to see the effect of this PI3K inhibitor on HIFa stabilization. SF2523 blocked accumulation of HIF1a and HIF2a in dose-dependent manner (Fig. 2C ), which correlates with the decreased VEGF mRNA in BMDMs treated with SF2523 ( Fig. 2D ). To determine the role of AKT in hypoxic HIFa accumulation, experiments were performed where AKT is either knocked down or an activated membrane-targeted AKT (myrAKT) is exogenously expressed in BMDMs. Figure 2E and F showed that knockdown of AKT using siRNA blocked accumulation of HIFa, whereas exogenous expression of myrAKT increased HIFa levels.
Specific p110d and p110 g isoforms of PI3K control HIFa/VEGF axis in macrophages We next focused on the specific isoforms of PI3K involved in regulating the HIFa/VEGF axis in macrophages. Recently, published reports (26) and our results provide evidence that p110g is the predominant isoform expressed in the myeloid cells and macrophages ( Supplementary Fig. S1A ).
To determine the specificity of the PI3K signaling in HIFa accumulation isoform-specific PI3K inhibitors, namely, GDC-0941 (p110a-specific inhibitor; ref. 36 ), TGX-221 (p110b-specific inhibitor; ref. 37 ), Cal101 (p110d-specific inhibitor; ref. 38 ) and AS605240 (p110g-specific inhibitor; ref. 39) were used. Interestingly, we found that AS605240 (a p110g isoform inhibitor) showed the most marked inhibition of HIFa accumulation and decreased the transcriptional activation of VEGF in BMDMs, whereas the effect of inhibitors of a, b, and d isoform did not show a marked effect on HIFa accumulation ( Fig. 3A and B ). However, inhibitors of a, b, and d isoform significantly blocked VEGF mRNA expression. Although isoform-specific inhibitors of PI3K display some level of selectivity, the kinase inhibitory profiles and IC 50 potencies against different p110 isoforms are not absolute, making conclusions difficult. To confirm a specific role for different PI3K catalytic isoforms in the regulation of HIF1a accumulation, we therefore knocked down the expression of p110 isoforms in BMDMs by using siRNA against these isoforms. As shown in Fig. 3C and D, targeting of specific p110g isoform led to decreased hypoxiainduced HIFa stabilization and reduced expression of VEGF mRNA, whereas there is no effect on HIFa protein and VEGF mRNA levels on targeting a and b isoforms. Interestingly, knockdown of p110d isoform also blocked accumulation of HIFa protein as well as VEGF gene expression ( Fig. 3C and D) . Taken together, these results support that HIFa stability is mainly contributed by p110g isoform and partially by p110d isoform of PI3K. To validate our results that p110g is the major isoform involved in regulating HIFa stability, we used p110g À/À mice. The BMDMs isolated from these mice show decreased HIFa accumulation and VEGF secretion ( Fig. 3E and F) . However, p110g À/À BMDMs treated with AS605240 (p110g-specific inhibitor) did not show any further reduction in VEGF levels (Fig. 3F ), further validating our results that p110g is the major isoform involved in HIFa accumulation and VEGF secretion.
Blocking PI3K signaling axis induces the hypoxic degradation of HIFa via the 26S proteasome pathway
The above results (Figs. 1-3) clearly establish a key role for the PTEN/PI3K signaling pathway in hypoxiainduced HIFa accumulation in macrophages. To explore the mechanism by which PTEN/PI3K pathway affects HIFa levels in macrophages, we used the proteasome inhibitor, MG132 to ask whether this process was related to proteasome-dependent degradation of HIF. BMDMs from PTEN MC-WT and PTEN MC-KO mice were treated with the proteasome inhibitor, MG132, before exposure to hypoxia. Our data support the hypothesis that PTEN affects HIFa under hypoxic conditions by inducing the hypoxic degradation of HIFa as this effect can be reversed by pretreatment with the proteasome inhibitor, MG132 (Fig. 4A ). To further confirm that the disappearance of HIFa is a proteasome-dependent event and that PI3K activation is required for the hypoxic stability of HIFa, we treated macrophages with a panel of PI3K inhibitors. The decrease in HIFa accumulation observed in BMDMs treated with pan-PI3K inhibitors, p110g isoform-specific PI3K inhibitor, AS605240, and novel pan-PI3K inhibitor, SF2523, was reversed by treatment with MG132 ( Fig.  4B-D) . The degradation of HIFa by VHL under normoxic conditions is well known; however, its degradation under hypoxia is poorly understood. Importantly, our results provide direct evidence that HIFa is degraded under hypoxic conditions in a PTEN-and PI3K-dependent manner in macrophages.
PI3Kg signaling in macrophages promotes tumor growth and metastasis
It is well documented that macrophages exposed to hypoxia accumulate both HIF1a and HIF2a, and overexpression of HIF2a in TAMs is specifically correlated with high-grade human tumors and poor prognosis (9). On the same note, Doedens and colleagues reported that macrophage expression of HIF1a suppresses T-cell function and promotes tumor growth (40) . On the basis of the results observed in the present study showing the important role of PI3K signaling axis in controlling both HIF1a and HIF2a accumulation in macrophages, we hypothesize that PI3K signaling should promote tumor growth by increasing secretion of proangiogenic factors in TAMs. To validate this hypothesis, syngeneic LLC was injected subcutaneously into WT and p110 gÀ/À mice. Tumor growth and angiogenesis were drastically reduced in p110g À/À mice ( Fig. 5A and B) . Immunofluorescence CD31 staining showed that the microvessel density was significantly reduced in tumors propagated in p110g À/À mice (Fig. 5B ). On the basis of previously published report that p110g is the isoform predominantly expressed in myeloid cell compartment (26) and our observation that p110g isoform is the major contributor of hypoxia-induced both HIF1a and HIF2a accumulation in macrophages ( Fig. 3C-F) , we hypothesized that macrophages infiltrating into the tumors implanted in p110g À/ À mice would be defective in secretion of proangiogenic factors that promote tumor growth. To validate this hypothesis, macrophages were FACS sorted (on the basis of CD11b and F4/80 staining) from LLC tumors implanted in WT and p110g À/À mice and evaluated for expression of genes required for tumor growth and progression. For this, a panel of TAM-associated genes, VEGF, matrix metalloproteinase (MMP)9, urokinase-type plasminogen activator (uPA), COX2, arginase, MMR, TGFb, IL1, and TNFa, was used to examine the gene expression profile of macrophages present in the tumor microenvironment of WT and p110g À/À mice. The expression levels of COX2, uPA, MMP9, MMR, arginase, and VEGF are significantly higher in macrophages sorted from LLC tumors of WT than in p110g À/À mice (Fig. 5C ). In contrast, the macrophages sorted from tumors implanted in p110g À/À animals showed higher levels of IL1 and TNFa (Fig. 5C ). Consistent with this, existing literature suggests that TAMs secrete several proteins including MMP-9 (41), uPA (42) , and VEGF (43), which promote tumor growth, angiogenesis, and metastasis. IL1 and TNFa are proinflammatory cytokines which are reported to be expressed at a lower level in tumor-associated M2 macrophages and are known to promote tumor suppression (44) . These results suggest that macrophages isolated from tumors implanted in p110g À/À mice express higher levels of proinflammatory cytokines seen in M1 macrophages which promote tumor suppression, whereas macrophages isolated from WT mice show higher expression of genes which promote tumor growth and progression. Tumor growth and angiogenesis are prerequisites for metastasis; hence, we examined whether p110g À/À mice display . Specific p110g and p110d isoform of PI3K control HIFa/VEGF axis in macrophages. A and B, BMDM from WT animals were treated with 100 nmol/L of GDC0941or TGX221or Cal101 or AS605240 followed by hypoxia for 4 hours for Western blot analysis or 24 hours for RNA isolation and real-time PCR analysis. C and D, BMDMs from WT animals were transfected with either 100 nmol/L control siRNA or siRNA against p110 a or b or d or g isoform using Amaxa Mouse Macrophage Nucleofaction kit (Lonza). Thirty-six hours after transfection, hypoxia was given to these siRNA-transfected BMDMs for 4 hours for Western blot analysis (C) or 24 hours for RNA isolation and real-time PCR analysis (D). E, Western blot analysis of HIF1a and HIF2a from WT and p110g À/À BMDMs kept in hypoxic (1% O2) conditions for 4 hours followed by preparation of nuclear extracts. Each lane in figure represents lysate prepared from an individual mouse. F, relative VEGF expression in WT, p110 g À/À BMDMs treated with or without 100 nmol/L AS605240 and kept in hypoxia (1% O2) for 24 hours, followed by RNA isolation and real-time PCR studies. Graphs in B, D, and F represent mean AE SEM (n ¼ 4-5) for 3 independent experiments. Statistical significance is assessed by 2-sample t test. Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001.
any defect in metastasis. To explore the role of p110g in experimental lung metastasis, B16F10 melanoma cells were injected into mouse tail veins of WT and p110g À/À animals. Two weeks later, we observed massive numbers of metastatic foci in the lungs of WT mice compared with a marked reduction in number of nodules in p110g À/À mice (Fig. 5D) . A microscopic analysis of lung tissue sections confirmed the results from gross specimens and demonstrated larger numbers of metastatic foci in the lungs of WT mice (Fig. 5D ). These observations led us to examine whether the BMDMs prepared from p110g À/À mice in vitro display any defect in expression of genes promoting tumor growth and progression. We found that macrophages isolated from LLC tumors growing in p110g À/À mice were defective in the expression of genes previously implicated in the promotion of tumor growth (M2 markers; Fig. 5E ) including VEGF described in Fig. 3F .
SF1126, a pan-PI3K inhibitor, blocks tumor growth and metastasis and reduces the expression of proangiogenic factors by TAMs
Considering the role of PTEN and PI3K signaling in the macrophage-dependent promotion of tumor growth and tumor-induced angiogenesis, we examined the effects of a pan-PI3K inhibitor, SF1126, in the LLC model for its effects on tumor growth, angiogenesis, and metastasis in vivo (Fig. 6 ). SF1126 has completed phase I clinical trial in solid tumors and B-cell malignancies and is headed for a phase II trial in 2014 (29) . The administration of 50 mg/kg dose of SF1126, 3 times a week, significantly blocked tumor growth in WT animals implanted with LLC ( Fig. 6A ). Hence, we determined whether SF1126 exerts an effect on the neovascularization of these tumors. Immunofluoresence CD31 staining showed that the microvessel density was significantly reduced in the mice treated with SF1126 ( Fig. 6B ). Because TAMs are known to have a marked influence on the regulation of tumorinduced angiogenesis (45) , we propose that SF1126 blocks angiogenesis in the tumors by blocking the proangiogenic factors secreted by TAMs within the tumor microenvironment. The supporting evidence for this notion comes from the real-time PCR data obtained from macrophages (FACS sorted on basis of CD11b and F4/80 staining) isolated from the LLC tumors implanted into WT mice and treated with or without SF1126 (Fig. 6C) . Interestingly, the macrophages sorted from the mice treated with SF1126 inhibitor showed reduced expression of VEGF, MMP9, arginase, and COX2 (Fig. 6C) . The results in Fig.  6C suggest that macrophages isolated from SF1126-treated tumors display a reduced expression of proangiogenic factors promoting metastasis. So, we next explored whether the administration of SF1126 can block tumor metastasis. We observed a marked increase in metastatic foci in the lungs of WT mice compared with the 60% reduction in metastatic nodules seen in SF1126-treated mice injected with B16F10 melanoma (P < 0.01; Fig. 6D and E). Our results demonstrating that SF1126 blocked metastasis lead us to explore the effect of SF1126 on survival in the B16 experimental metastasis model. The data in Fig. 6F demonstrate that SF1126 treatment prolongs the survival of mice by average 15 days, a result which directly correlates with the inhibition of experimental metastasis in this model and validating the efficacy of this drug either alone or in combination with other drugs in the treatment of cancer. Taken together, we conclude that SF1126 blocks tumor growth and metastasis potentially by blocking HIF1a and HIF2a and the downstream expression and secretion of proangiogenic factors by tumor-infiltrating M2 macrophages. On the basis of these results, we propose a hypothetical model in which E3 ligase degrades HIF1a under hypoxic conditions in the cytoplasm in a proteasome-dependent manner. The model would predict that the stimulation of PI3K and AKT via upstream signals will serve to promote translocation of E3 ligase into the nucleus and hence promote the stabilization of hypoxic HIF1a. The pathway will bring hypoxic HIF1a under the control of the PTEN/ PI3K/AKT signaling axis to regulate an E3 ligase to control hypoxic HIF1a levels and angiogenesis and tumor metastasis in vivo (Fig. 7) .
Discussion
It is well established that TAMs accumulate in hypoxic regions of tumors and that hypoxia triggers a proangiogenic program in these cells stimulating the production of angiogenic factors and matrix-regulatory proteins such as VEGF and MMPs, respectively (46, 47) . Therefore, macrophages Figure 5 . Expression of p110g isoform in macrophages promotes tumor growth and angiogenesis. A, tumor growth of LLC cells inoculated subcutaneously in WT and p110g À/À mice (n ¼ 6-8). B, left, representative immunofluorescent staining of tumor vasculature by CD31 (green) and counterstain by DAPI (blue) on frozen tumor sections of LLC tumors implanted subcutaneously in WT and p110g À/À mice. Right, reduced microvascular density (MVD) in tumors isolated from p110g À/À animals as compared with WT animals. MVD was determined by counting the number of microvessels per high-power field (HPF) in the section with an antibody reactive to CD31. Microvessels were counted blindly in 5 to 10 randomly chosen fields, and data are representative of 3 independent experiments with 4 to 5 mice. Ã , P < 0.05 versus WT. C, relative expression levels of specific genes required for tumor growth in macrophages sorted from LLC tumors implanted into WT and p110g À/À animals. D, left, representative photograph of pulmonary metastatic foci produced 15 days after intravenous injection of B16F10 cells in WT and p110g À/À mice. Right, number of experimental pulmonary B16F10 metastases in lungs counted under dissecting microscope.
recruited in situ represent an indirect pathway of amplification of angiogenesis, in concert with angiogenic molecules directly produced by tumor cells. Thus, we speculate that targeting the common pathway promoting angiogenesis in macrophages as well as tumor cell compartment will likely provide more effective therapy in the treatment of cancer. The PI3K pathway is known to play a critical role in tumor cell survival, angiogenesis, invasion, apoptosis, and cellular metabolism (15, 22) and is considered as the most frequently activated pathway in cancer. Herein, we provide direct evidence that PI3K pathway controls tumor growth and angiogenesis and regulates the HIFa/VEGF axis in macrophages. Moreover, SF1126, a pan-PI3K inhibitor entering phase II clinical trials, blocks macrophage-mediated tumor growth, angiogenesis, and metastasis, suggesting efficacy of SF1126 and other PI3K inhibitors in the treatment of cancer in which macrophages are important in tumor progression. Recent studies have clearly demonstrated that HIF1a and HIF2a are stabilized in hypoxic macrophages in vitro (12) . Talks and colleagues demonstrated that HIF2a protein accumulates at high levels in TAMs detected in various human cancers (9) . Recent reports suggest the important role Figure 6 . SF1126, a pan-PI3K inhibitor blocks tumor growth, angiogenesis, metastasis and reduces the expression of proangiogenic factors by TAMs. A, tumor volume of LLC inoculated subcutaneously in WT mice treated with or without 50 mg/kg SF1126 3 times a week. Treatment was started 10 days after inoculation of LLC cells and was continued until tumors were harvested (n ¼ 6-8). B, MVD was scored by manual counting of CD31-positive vessels in subcutaneous LLC tumor sections was reduced in tumors isolated from WT animals treated with SF1126. Right, reduced microvascular density in tumors isolated from untreated or SF1126-treated animals as confirmed by quantification of CD31-positive area in high-power field (HPF) C, relative expression levels of specific genes required for tumor growth in macrophages sorted from LLC tumors implanted into WT mice and treated with 50 mg/kg of SF1126, 3 times a week until tumors were harvested. D, left, representative photograph of pulmonary metastatic foci produced in WT animals injected with B16F10 melanoma and treated with daily dose of 50 mg/kg SF1126 for 15 days. Right, number of experimental pulmonary B16F10 metastases in lungs. E, figure shows representative lung hematoxylin and eosin (H&E) sections of B16 metastases from WT mice treated with or without 50 mg/kg SF1126. Arrows point to metastatic foci. F, Kaplan-Meier survival curve for B16 metastasized mice treated with or without 50 mg/kg SF1126 daily. Data are representative of 2 to 3 independent experiments. Graphs present mean AE SEM of 8 to 10 mice for A, B, and D-F and 3 to 4 mice for C. Ã , P < 0.05 and ÃÃ , P < 0.01 versus WT, as determined using 2-sample t test.
of HIF2a in macrophage functions in mouse models of tumor inflammation (48) . In the present study, using genetic mouse models, siRNA approach, and clinically relevant PI3K inhibitors, we provide evidence that PTEN/PI3K signaling controls both HIF1a and HIF2a accumulation in macrophages. The role of PTEN/PI3K signaling in promoting HIFa stabilization in tumor cells is well-documented. However, there are no reports examining the role of this important signaling axis in HIFa stabilization in macrophages. Our studies clearly demonstrate that the loss of PTEN in the myeloid cell compartment promotes hypoxic HIFa stabilization in BMDMs (Fig. 1) . Our studies provide convincing evidence that the expression of PTEN and inhibition of PI3K/AKT signaling induces the hypoxic degradation of HIF1a and HIF2a in a proteasome-dependent manner. While much is known about the transcriptional and posttranslational regulation of HIFa, there is very limited evidence that HIFa can be degraded under conditions of hypoxia by the 26S proteasome (49) . Liu and colleagues recently described oxygen-independent degradation of HIF1a by a novel HIF1a-interacting protein, receptor for activated C-kinase 1 (RACK1; ref. 50). They suggested that similar to the E3 ligase pVHL, RACK1 increased polyubiquitination of HIF1a and was unable to mediate degradation of HIF1a in the presence of protea-somal inhibitor MG132. In the same context, recent study suggests that SHARP promotes proteasomal degradation of HIF1a independent of pVHL, hypoxia, and ubiquitination machinery (51) . Recently published work from our laboratory performed in glioma tumor models has demonstrated that PTEN and PI3K inhibitors control the hypoxic degradation of HIF1a and that the E3 ligase, MDM2, is required for hypoxic degradation of HIF1a (52) The E3 ligase and other signaling pathways controlling the degradation of HIF1a and HIF2a under hypoxic conditions in macrophages remain an active area of investigation and will be a major focus of our future research efforts. Moreover, we observed that p110g, the most dominant isoform of PI3K expressed in macrophages, controls HIF1a and HIF2a accumulation in macrophages. Interestingly, our data provide evidence that p110d isoform contributes significantly to HIFa stabilization and VEGF secretion in BMDMs ( Fig. 3C and D) . More importantly, we demonstrate that the expression of p110g in macrophages promotes tumor growth and metastasis potentially by controlling the expression of proangiogenic and tumor growth-promoting factors by TAMs ( Fig. 5C and E) . A recent report by Schmid and colleagues has shown that p110g promotes tumor inflammation by controlling the trafficking of myeloid cells into tumor (26) . Our work extends these findings and suggests that the expression of p110g in macrophages controls the hypoxia-driven HIFa/VEGF axis which plays a crucial role in neovascularization and tumor growth. Moreover, our studies provide evidence that administration of SF1126 blocks macrophage-mediated tumor growth and angiogenesis. SF1126 has completed phase I clinical trial in B-cell malignancies and solid tumors with excellent safety profile (29) . It is currently slated for a phase II trial in PIK3CA-mutated human cancers. Herein, we demonstrate that SF1126 which potently blocks tumor proliferation and survival (29, 53) exerts a marked effect on the tumor stromal macrophage compartment as it blocks tumor growth, angiogenesis, and metastasis in vivo. In conclusion, the major findings of this article are: (i) we identified an important role of PTEN/PI3K/AKT signaling axis in HIF1a and HIF2a stabilization in macrophages; (ii) PTEN and several clinically relevant PI3K inhibitors exert their control over HIFa/ VEGF axis by inducing the hypoxic degradation of HIFa subunit in a proteasome-dependent manner; (iii) expression of p110g in macrophages promotes tumor growth and metastasis; and (iv) SF1126 potently blocked macrophage-mediated tumor angiogenesis and metastasis. These studies suggest that SF1126 and other PI3K inhibitors are excellent candidates for the treatment of cancers where macrophages promote tumor progression.
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